We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Sues J&J Over ‘Exclusionary Contracts’ to Block Biosimilar Infliximab
Pfizer Sues J&J Over ‘Exclusionary Contracts’ to Block Biosimilar Infliximab
Pfizer is suing Johnson & Johnson over its contracts and rebate policies with insurers and hospitals, saying they are designed to block sales of a biosimilar for J&J’s blockbuster Remicade therapy.